Mandate

Vinge advises Axcel VI and Currentum in connection with the acquisition of the Ipart Group

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of the Ipart Group which includes the companies SP-gruppen AB, Klimatentreprenad Värmland AB, Rörinstallationer i Karlstad AB, Ulvsby Rör AB, MeR El AB, and GÖREL Norden AB.

The companies provide services within ventilation, heating and sanitation, electricity and safety and are based in the western and central parts of Sweden. The Ipart Group has a turnover of approximately SEK 350 million and approximately 100 employees. Following the acquisition, Currentum is expected to have a turnover of approximately SEK 2.5 billion and will engage just over 900 employees. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted of partner Christina Kokko together with Karl Klackenberg, Hannah Kajlinger, and Linnea Petersson (M&A), Isak Willborg (Construction), Elin Broman (Employment), Michaela Ådén (Financing), Ulf Pyk (Real Estate) and Julia Hagelberg (Project and VDR Assistant).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026